TMCnet News

Research and Markets: Metastatic Breast Cancer - Pipeline Review, H1 2014: 83 Companies Profile
[May 08, 2014]

Research and Markets: Metastatic Breast Cancer - Pipeline Review, H1 2014: 83 Companies Profile


DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/tz2c98/metastatic_breast) has announced the addition of the "Metastatic Breast Cancer - Pipeline Review, H1 2014" report to their offering.

This report provides comprehensive information on the therapeutic development for Metastatic Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Breast Cancer and special features on late-stage and discontinued projects.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Metastatic Breast Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, oA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Metastatic Breast Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Metastatic Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Metastatic Breast Cancer pipeline on the basis of target, MoA, route of administration and molecule type



Companies Mentioned:

  • Adherex Technologies Inc.
  • Advaxis, Inc.
  • Advenchen Laboratories, LLC
  • Agonox
  • AlphaMab Co., Ltd
  • Amarna Therapeutics B.V.
  • Amgen Inc.
  • Aphios Corporation
  • Array BioPharma Inc.
  • Aslan Pharmaceuticals Pte. Ltd.
  • AstraZeneca PLC
  • Bavarian Nordic A/S
  • BioMarin Pharmaceutical Inc.
  • BioNumerik Pharmaceuticals, Inc.
  • Biocon Limited
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Cell Therapeutics, Inc.
  • Celldex Therapeutics, Inc.
  • Celltrion, Inc.
  • Corcept Therapeutics Incorporated
  • Curadis GmbH
  • Curaxys, S.L.
  • Dainippon Sumitomo Pharma Co., Ltd.
  • Dompe Farmaceutici S.p.A.
  • EirGen Pharma Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.

and much more...


For more information visit http://www.researchandmarkets.com/research/tz2c98/metastatic_breast


[ Back To TMCnet.com's Homepage ]